U.S. Peptide Drug Conjugates Market Size & Outlook
U.S. peptide drug conjugates market, 2018-2030 (US$M)
Related Markets
U.S. peptide drug conjugates market highlights
- The U.S. peptide drug conjugates market generated a revenue of USD 304.2 million in 2023 and is expected to reach USD 1,682.5 million by 2030.
- The U.S. market is expected to grow at a CAGR of 27.7% from 2024 to 2030.
- In terms of segment, therapeutics was the largest revenue generating type in 2023.
- Therapeutics is the most lucrative type segment registering the fastest growth during the forecast period.
Peptide drug conjugates market data book summary
| Market revenue in 2023 | USD 304.2 million |
| Market revenue in 2030 | USD 1,682.5 million |
| Growth rate | 27.7% (CAGR from 2023 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Therapeutics |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Therapeutics, Diagnostics |
| Key market players worldwide | Novartis AG ADR, Oncopeptides AB, Bicycle Therapeutics PLC ADR, AstraZeneca PLC, Theratechnologies Inc, Cybrexa Therapeutics, AngioChem, Soricimed |
Other key industry trends
- In terms of revenue, U.S. accounted for 42.0% of the global peptide drug conjugates market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. peptide drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 154.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peptide Drug Conjugates Market Scope
Peptide Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. peptide drug conjugates market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide drug conjugates market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.49% in 2023. Horizon Databook has segmented the U.S. peptide drug conjugates market based on therapeutics, diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
In 2022, the U.S. played a pivotal role in driving the peptide drug conjugates market revenue. This dominance can be attributed to the rapid advancements in technology, recent approvals by the U.S. FDA for peptide-based drugs, and fierce competition among companies.
These factors are expected to significantly propel the market growth during the forecast period. Several strategic initiatives are being undertaken in the market. For instance, in November 2022, Cybrexa Therapeutics (Cybrexa) and Exelixis, Inc. collaborated, which gave Exelixis an exclusive potential right to acquire CBX-12 (alphalex exatecan), a cutting-edge clinical-stage peptide drug conjugate.
The novel approach leverages Cybrexa’s proprietary alphalex technology, enhancing the precision of exatecan delivery to tumor cells. CBX-12's formulation strategically augments the efficiency of topoisomerase I inhibition while simultaneously mitigating its toxicity.
Reasons to subscribe to U.S. peptide drug conjugates market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. peptide drug conjugates market databook
-
Our clientele includes a mix of peptide drug conjugates market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. peptide drug conjugates market , including forecasts for subscribers. This country databook contains high-level insights into U.S. peptide drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. peptide drug conjugates market size, by type, 2018-2030 (US$M)
U.S. Peptide Drug Conjugates Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
